BNC105-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBNC105Cat. No.: HY-16114CAS No.: 945771-74-4分式: CHO分量: 372.37作靶点: Microtubule/Tubulin作通路: Cell Cycle/DNA Damage; Cytoskeleton储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 25 mg/mL (67.14

2、mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.71 mM); Suspended solution; Need ultrasonic and warming2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.71 mM); Suspended solution; Need ultrasonic and warming3. 请依序添加每种溶剂： 10% DMSO 90% corn

3、oil1/2 Master of Small Molecules 您边的抑制剂师www.MedChemESolubility: 2.5 mg/mL (6.71 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 BNC105种具有抗增殖和破坏肿瘤管功能的，微管蛋聚合抑制剂。IC50 & Target BNC105 exhibited excellent potency against a panel of different cancer cell lines with IC50 1 nM for DU145,Calu-6, MDA-MB-231 etc. Th

4、e selectivity observed for BNC105 against activated over quiescent HUVECswas also observed in human aortic arterial endothelial cells (HAAECs). BNC105 also exhibited good potencytoward the cisplatin resistant cell line A2780cis.REFERENCES1. Flynn BL, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-

5、3-(3,4,5-trimethoxybenzoyl)benzobfuran (BNC105), a tubulinpolymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011 Sep 8;54(17):6014-27.2. Kremmidiotis G, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor

6、vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010 Jun;9(6):1562-73.3. Inglis DJ, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther. 2014;15(11):1552-60.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400